Fajardo-Ramírez ÓR, Ascacio-Martínez JAI, Licea-Navarro AF, Villela-Martínez LM, Barrera-Saldaña HA

Idioma: Ingles.
Referencias bibliográficas: 88
Paginas: 158-169
Archivo PDF: 287.75 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Bradbury RH, Angibaud P. Cancer. Berlin; New York: Springer; 2007.

2. Peterson E, De P, Nuttall R. BMI, diet and female reproductive factors as risks for thyroid cancer: a systematic review. PLoS One. 2012;7:e29177.

3. Wondrak GT. Redox-directed cancer therapeutics: molecular mechanisms and opportunities. Antioxid Redox Signal. 2009;11: 3013-69.

4. Abidin AZ, Garassino MC, Califano R, Harle A, Blackhall F. Targeted therapies in small cell lung cancer: a review. Ther Adv Med Oncol. 2010;2:25-37.

5. Das R, Morrow J. Antibody therapeutics: product development, market trends, and strategic issues. Westborough, MA: D&MD Publications; 2004.

6. Daguet A, Watier H. 2nd Charles Richet et Jules Hericourt workshop: therapeutic antibodies and anaphylaxis; May 31-June 1, 2011, Tours, France. MAbs. 2011;3(5):417-21.

7. Shakir EM, Cheung DS, Grayson MH. Mechanisms of immunotherapy: a historical perspective. Ann Allergy Asthma Immunol. 2010;105:340-7; quiz 8, 68.

8. Lindstrom GA. An Experimental Study of Myelotoxic Sera. Therapeutic attempts in chronic myeloid leukaemia. Acta Med Scand Suppl. 1927;22.

9. Oldham RK, Dillman RO. Principles of cancer biotherapy. 5th ed. Dordrecht: Springer; 2009.

10. Little M. Recombinant antibodies for immunotherapy. New York: Cambridge University Press; 2009.

11. Dimitrov AS. Therapeutic antibodies: methods and protocols. New York, NY: Humana; 2009.

12. Iwase H. Current topics and perspectives in the treatment of endocrine-related cancers. Int J Clin Oncol. 2008;13:377-9.

13. Carey K. Biosimilars encircle Rituxan, US debates innovator exclusivity. Nat Biotechnol. 2011;29:177-8.

14. Kay J. Biosimilars: a regulatory perspective from America. Arthritis Res Ther. 2011;13:112.

15. Kopp-Kubel S. International Nonproprietary Names (INN) for pharmaceutical substances. Bull World Health Organ. 1995;73:275-9.

16. Riley JK, Sliwkowski MX. CD20: a gene in search of a function. Semin Oncol. 2000;27(Suppl 12):17-24. Table 1. Biotech companies that are currently developing antibody derived fragments Company Technology platform Mechanism Macrogenics DART® (dual-affinity re-targeting) platform Dual specificity ‘antibody-like’ therapeutic proteins capable of targeting many different epitopes with a single recombinant molecule. f-star Modular antibody technology Allows small antibody fragments with full antibody functionality (Fcab) or full-length antibodies with additional functionality (mAb) to be created. Amgen BiTE® (bispecific T-cell engager) technology Lead product blinatumomab (MT-103) is a BiTE® antibody designed to direct T-cells against CD19 on B-cell-derived acute lymphoblastic leukemia and non-Hodgkin’s lymphomas. Bicycle Therapeutics Bicycle technology Mini-antibodies with two binding loops covalently attached to organochemical cores. Domantis/GSK Dual targeting dAbs The fully human dual targeting dAbs bind two targets simultaneously and can be manufactured in dimer, Fab-like or IgG-like formats. Domantis is developing dual targeting factors for solid tumors tumor antigens on tumor cells and angiogenic dAbs against cytokines for inflammatory diseases, tumor antigens on tumor cells and angiogenic factors for solid tumors. dAb: domain antibody; Ig: immunoglobulin.

17. Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today. 1994;15:450-4.

18. Kehrl JH, Riva A, Wilson GL, Thevenin C. Molecular mechanisms regulating CD19, CD20 and CD22 gene expression. Immunol Today. 1994;15:432-6.

19. Martin P, Furman RR, Coleman M, Leonard JP. Phase I to III trials of anti-B cell therapy in non-Hodgkin’s lymphoma. Clin Cancer Res. 2007;13:5636-42s.

20. St Clair EW. Novel targeted therapies for autoimmunity. Curr Opin Immunol. 2009;2:648-57.

21. Weiner GJ. Rituximab: mechanism of action. Semin Hematol. 2010;47:115-23.

22. Ray GL, Baidoo KE, Keller LM, Albert PS, Brechbiel MW, Milenic DE. Pre-clinical assessment of lu-labeled trastuzumab targeting HER2 for treatment and management of cancer patients with disseminated intraperitoneal disease. Pharmaceuticals (Basel). 2011;5:1-15.

23. Milenic DE, Garmestani K, Brady ED, et al. Targeting of HER2 antigen for the treatment of disseminated peritoneal disease. Clin Cancer Res. 2004;10:7834-41.

24. Wykosky J, Fenton T, Furnari F, Cavenee WK. Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations. Chin J Cancer. 2011;30:5-12.

25. Robinson MK, Hodge KM, Horak E, et al. Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. Br J Cancer. 2008;99:1415-25.

26. Van Laethem JL. Cetuximab. Drugs. 2004;64:119.

27. Scartozzi M, Bearzi I, Mandolesi A, et al. Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. Br J Cancer. 2011; 104:1786-90.

28. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol. 2005;23:1147-57.

29. Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: A multicenter phase II trial. J Clin Oncol. 2004;22: 2610-6.

30. Van Cutsem EJD, Tabemero J, Diaz-Rubio E, et al. An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing epidermal growth factor receptor (EGFR). Ann Oncol. 2004;15:91.

31. Trigo J, Hitt R, Koralewski P, et al. Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/ metastatic squamous cell carcinoma of the head and neck (SCCHN): Results of a phase II study. J Clin Oncol. 2004;22:488s.

32. Tabernero JM, Van Cutsem E, Sastre J, et al. An international phase II study of cetuximab in combination with oxaliplatin/5- fluorouracil (5-FU/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing epidermal growth factor receptor (EGFR). Preliminary results. J Clin Oncol. 2004;22:248s.

33. Saltz LB, Meropol NJ, Loehrer PJ, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22:1201-8.

34. Rosell R, Daniel C, Ramlau R, et al. Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC). J Clin Oncol. 2004;22:620s.

35. Hohler T, Dittrich C, Lordick F, et al. A phase I/II study of cetuximab in combination with 5-fluorouracil (5-FU)/folinic acid (FA) plus weekly oxaliplatin (L-OHP) (FUFOX) in the first-line treatment of patients with metastatic colorectal cancer (mCRC) expressing epidermal growth factor receptor (EGFR). Preliminary results. Ann Oncol. 2004;15:69-70.

36. Harari PM, Giralt JL, Chinnaiyan P, et al. Results of an international phase III trial of radiation +/- Cetuximab (Erbitux (TM)) in patients with locoregionally advanced head & neck (H & N) cancer. Ann Oncol. 2004;15:13.

37. Giralt J, Haran PM, Ang KK, et al. A phase III study of high dose radiation therapy with or without cetuximab in patients with locoregionally advanced squamous cell carcinoma of the head and neck. Radiother Oncol. 2004;73:S127.

38. Bonner JA, Giralt J, Harari PM, et al. Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer. Int J Radiat Oncol. 2004;60:S147-8.

39. Weiner LM, Dhodapkar MV, Ferrone S. Monoclonal antibodies for cancer immunotherapy. Lancet. 2009;373:1033-40.

40. Bonavida B. What signals are generated by anti-CD20 antibody therapy? Curr Hematol Malig Rep. 2006;1:205-13.

41. Lutterbuese R, Raum T, Kischel R, et al. T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAFmutated colorectal cancer cells. Proc Natl Acad Sci USA. 2010; 107:12605-10.

42. Weiner GJ. Monoclonal antibody mechanisms of action in cancer. Immunol Res. 2007;39:271-8.

43. Lisi S, Sisto M, Lofrumento DD, D’Amore S, D’Amore M. Advances in the understanding of the Fc gamma receptors-mediated autoantibodies uptake. Clin Exp Med. 2011;11:1-10.

44. Cardarelli PM, Rao-Naik C, Chen S, et al. A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies. Cancer Immunol Immunother. 2010;59:257-65.

45. Isaacs JD. Antibody engineering to develop new antirheumatic therapies. Arthritis Res Ther. 2009;11:225.

46. Reichert JM. Trends in the development of therapeutic anticytokine antibodies. Drug Discov Today. 2004;9:348.

47. Lynch RG. Regulatory roles for FcgammaRIII (CD16) and FcgammaRII (CD32) in the development of T- and B-lineage lymphoid cells. J Leukoc Biol. 2000;67:279-84.

48. Abbas AK, Lichtman AH, Pillai S. Cellular and molecular immunology. 6th ed. Philadelphia: Saunders/Elsevier; 2010.

49. Luo J, Obmolova G, Huang A, et al. Coevolution of antibody stability and Vkappa CDR-L3 canonical structure. J Mol Biol. 2010;402:708-19.

50. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol. 2006;6:343-57.

51. Lo BK. Antibody humanization by CDR grafting. Methods Mol Biol. 2004;248:135-59.

52. Carmen S, Jermutus L. Concepts in antibody phage display. Brief Funct Genomic Proteomic. 2002;1:189-203.

53. Stemmer WP. DNA shuffling by random fragmentation and reassembly: in vitro recombination for molecular evolution. Proc Natl Acad Sci USA. 1994;91:10747-51.

54. Hawkins RE, Russell SJ, Winter G. Selection of phage antibodies by binding affinity. Mimicking affinity maturation. J Mol Biol. 1992;226:889-96.

55. Schier R, McCall A, Adams GP, et al. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J Mol Biol. 1996;263:551-67.

56. Boder ET, Midelfort KS, Wittrup KD. Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. Proc Natl Acad Sci USA. 2000;97:10701-5.

57. Steidl S, Ratsch O, Brocks B, Durr M, Thomassen-Wolf E. In vitro affinity maturation of human GM-CSF antibodies by targeted CDR-diversification. Mol Immunol. 2008;46:135-44.

58. Brekke OH, Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov. 2003;2:52-62.

59. Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol. 2009;157:220-33.

60. Chames P, Baty D. Bispecific antibodies for cancer therapy: the light at the end of the tunnel? MAbs. 2009;1:539-47.

61. Baeuerle PA, Kufer P, Bargou R. BiTE: Teaching antibodies to engage T-cells for cancer therapy. Curr Opin Mol Ther. 2009; 11:22-30.

62. Moran N. Boehringer splashes out on bispecific antibody platforms. Nat Biotechnol. 2011;29:5-6.

63. Keler T, Graziano RF, Mandal A, et al. Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells. Cancer Res. 1997;57:4008-14.

64. Shahied LS, Tang Y, Alpaugh RK, Somer R, Greenspon D, Weiner LM. Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format. J Biol Chem. 2004;279:53907-14.

65. Wolf E, Hofmeister R, Kufer P, Schlereth B, Baeuerle PA. BiTEs: bispecific antibody constructs with unique anti-tumor activity. Drug Discov Today. 2005;10:1237-44.

66. Nielsen UB, Adams GP, Weiner LM, Marks JD. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity. Cancer Res. 2000; 60:6434-40.

67. Mack M, Riethmuller G, Kufer P. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl AcadSci USA. 1995; 92:7021-5.

68. Buhler P, Wolf P, Gierschner D, et al. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells. Cancer Immunol Immunother. 2008;57:43-52.

69. Riano-Umbarila L, Contreras-Ferrat G, Olamendi-Portugal T, et al. Exploiting cross-reactivity to neutralize two different scorpion venoms with one single chain antibody fragment. J Biol Chem. 2011;286:6143-51.

70. Stork R, Campigna E, Robert B, Muller D, Kontermann RE. Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives. J Biol Chem. 2009;284:25612-9.

71. Kellner C, Bruenke J, Horner H, et al. Heterodimeric bispecific antibody-derivatives against CD19 and CD16 induce effective antibody-dependent cellular cytotoxicity against B-lymphoid tumor cells. Cancer Lett. 2011;303:128-39.

72. Cochlovius B, Kipriyanov SM, Stassar MJ, et al. Treatment of human B cell lymphoma xenografts with a CD3 x CD19 diabody and T cells. J Immunol. 2000;165:888-95.

73. Figini M, Martin F, Ferri R, et al. Conversion of murine antibodies to human antibodies and their optimization for ovarian cancer therapy targeted to the folate receptor. Cancer Immunol Immunother. 2009;58:531-46.

74. Topp MS, Kufer P, Gokbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29:2493-8.

75. Molhoj M, Crommer S, Brischwein K, et al. CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis. Mol Immunol. 2007; 44:1935-43.

76. Moore PA, Zhang W, Rainey GJ, et al. Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. Blood. 2011;117:4542-51.

77. Johnson S, Burke S, Huang L, et al. Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion. J Mol Biol. 2010;399: 436-49.

78. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol. 2005;23:1126-36.

79. Flajnik MF, Dooley H. The generation and selection of singledomain, v region libraries from nurse sharks. Methods Mol Biol. 2009;562:71-82.

80. Harmsen MM, van Solt CB, Fijten HP. Enhancement of toxin- and virus-neutralizing capacity of single-domain antibody fragments by N-glycosylation. Appl Microbiol Biotechnol. 2009; 84:1087-94.

81. Van den Abbeele A, De Clercq S, De Ganck A, et al. A llamaderived gelsolin single-domain antibody blocks gelsolin-G-actin interaction. Cell Mol Life Sci. 2010;67:1519-35.

82. Wesolowski J, Alzogaray V, Reyelt J, et al. Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Med Microbiol Immunol. 2009;198: 157-74.

83. Cortez-Retamozo V, Lauwereys M, Hassanzadeh Gh G, et al. Efficient tumor targeting by single-domain antibody fragments of camels. Int J Cancer. 2002;98:456-62.

84. De Genst E, Saerens D, Muyldermans S, Conrath K. Antibody repertoire development in camelids. Dev Comp Immunol. 2006; 30:187-98.

85. Van Broekhoven A, Shapiro F, Anné J. Novel frontiers in the production of compounds for biomedical use. Dordrecht; Boston, MA: Kluwer Academic Pub.; 2001.

86. Deal watch: Ablynx and Merck Serono collaborate on next-generation antibody products. Nat Rev Drug Discov. 2008;7:881.

87. Wolfson W. Ablynx makes nanobodies from llama bodies. Chem Biol. 2006;13:1243-4.

88. Ulrichts H, Silence K, Schoolmeester A, et al. Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs. Blood. 2011;118:757-65.